CTMX
CytomX Therapeutics, Inc.
Key Financials
Net Income
$-17368000
↓ 154.5%
Operating Income
$-22364000
↓ 189.5%
Revenue
$76.2M
↓ 44.8%
Total Liabilities
$52.6M
↓ 56.6%
Shareholders' Equity
$99.0M
↑ 21812.3%
Cash & Equivalents
$12.7M
↓ 66.7%
Long-term Debt
$1.6M
N/A
Total Assets
$151.6M
↑ 25.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| S-8 | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 3 | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 8/3/2026 | View on SEC |
| 4 | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CTMX |
| Company Name | CytomX Therapeutics, Inc. |
| CIK | 1501989 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650.515.3185 |